Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 57-63, 2022.
Artigo em Chinês | WPRIM | ID: wpr-940420

RESUMO

ObjectiveTo investigate the effect of Guiqi Baizhu prescription (GQBZ) combined with oxaliplatin on the expression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR2) and angiogenesis in gastric cancer-bearing mice. MethodThe tumor-bearing model of gastric cancer was induced in Kunming mice. The mice were randomly divided into blank group, model group, oxaliplatin group (10 mg·kg-1), and high- (17.68 g·kg-1), medium- (8.84 g·kg-1), and low-dose (4.42 g·kg-1) combination groups (GQBZ combined with oxaliplatin). After the last administration, the transplanted tumor was collected and the tumor inhibition rate was calculated. Hematoxylin-eosin (HE) staining was used to observe the morphological changes of tumor tissues. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum content of epidermal growth factor (EGF), interleukin-8 (IL-8), and vascular endothelial growth factor (VEGF). Western blot and immunohistochemistry (IHC) were used to detect the expression of EGFR, phosphorylated EGFR (p-EGFR), VEGFR2, phosphorylated VEGFR2 (p-VEGFR2), and platelet-endothelial cell adhesion molecule (CD31). Real-time fluorescence-based quantitative polymerase chain reaction (Real-time PCR) was used to detect the mRNA expression of EGFR and VEGFR2. ResultThe tumor weight in the drug intervention groups was significantly lower than that in the model group (P<0.01). Compared with the oxaliplatin group, the high- and medium-dose combination groups showed reduced tumor weight (P<0.05, P<0.01). The tumor cells in the model groups were high in cell density and regular in shape, and no clear tissue necrosis was seen. The tumor cell density in the drug intervention groups was reduced, and clear tissue necrosis and large-scale inflammatory cells were visible. Compared with the blank group, the model group and the drug intervention groups showed increased serum levels of EGF, VEGF, and IL-8 (P<0.05, P<0.01). Compared with the model group, the drug intervention groups showed decreased serum levels of EGF, VEGF, and IL-8 (P<0.01), reduced protein expression of EGFR, p-EGFR, VEGFR2, p-VEGFR2, and CD31, and declining mRNA expression of EGFR and VEGFR (P<0.01). Compared with the oxaliplatin group, the high- and medium-dose combination groups showed decreased serum levels of EGF, VEGF, and IL-8 (P<0.05, P<0.01), reduced protein expression of EGFR, p-EGFR, VEGFR2, p-VEGFR2, and CD31, and dwindled mRNA expression of EGFR and VEGFR2 (P<0.05, P<0.01). The low-dose combination group showed decreased serum levels of EGF, VEGF, and IL-8, reduced protein expression of EGFR, p-EGFR, VEGFR2, p-VEGFR2, and CD31, and dwindled mRNA expression of EGFR and VEGFR2, but the difference was not statistically significant. ConclusionGQBZ combined with oxaliplatin can inhibit the growth and angiogenesis of tumor tissues in gastric cancer-bearing mice by affecting the expression of EGFR and VEGFR2.

2.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 1-7, 2019.
Artigo em Chinês | WPRIM | ID: wpr-802158

RESUMO

Objective:To investigate the effect of modified Si Junzitang on angiogenesis in transplanted tumor of H22 tumor-bearing mice. Method:The effect of modified Si Junzitang on tumor inhibition and growth of peripheral blood vessels in tumor-bearing mice was observed by tumorigenesis experiment in mice. Hematoxylin-eosin (HE) staining and immunohistochemistry (IHC) were used to detect the distribution of blood vessels and the expression of vascular endothelial markers (CD31) in tumor-bearing mice. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR2) and tumor necrosis factor-α (TNF-α) in tumor tissue. Result:The inhibition rates of modified Sijunzi Tang in low-dose group (ig, 11.83 mg·kg-1·d-1), middle-dose group (ig, 23.66 mg·kg-1·d-1) and high-dose group (ig, 47.32 mg·kg-1·d-1) were 29.97%, 59.80%and 82.34%, respectively. Compared with the model group, the average tumor weight was lower in middle and high-dose groups, with statistically significant differences (PPPα in middle and high-dose modified Si Junzitang groups were lower than those in the model group (PConclusion:Modified Si Junzitang can inhibit the tumor growth of H22 tumor-bearing mice and the angiogenesis of transplanted tumors, which may be related to the reduction of TNF-α, VEGF and VEGFR2 expression levels.

3.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 48-55, 2019.
Artigo em Chinês | WPRIM | ID: wpr-801762

RESUMO

Objective: To observe the effects of Erchen on vascular endothelial growth factor (VEGF) and its receptor R2 (VEGFR2), interleukin (IL)-4 and endothelin-1 (ET-1) in rats with chronic obstructive pulmonary disease (COPD). Method: The 50 SD rats were randomly divided into 5 groups, 10 rats in each group, which were normal group, model group, Erchentang low, medium and high dose group (10, 20, 40 g · kg-1 · d-1). COPD rat model was established by smoking combined with lipopolysaccharide (LPS) intratracheal drip. After successful modeling, the treatment group was given intragastric administration, and the normal group and the model group were given intragastric distilled water of equal volume. The pathological changes of pulmonary vessels in rats were observed by light microscopy, and the thickness of pulmonary vascular wall was measured. The concentration of IL-4 in rat serum, bronchoalveolar lavage fluid (BALF) and lung homogenate was measured by enzyme-linked immunosorbent assay (ELISA). Real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) was used to detect the expression of ET-1 and immunohistochemistry was used to detect the expression of VEGF,VEGFR2 and ET-1 in lung tissue. Result: Compared with normal group, the concentration of IL-4 in serum, BALF and lung homogenate of model group rats decreased significantly (PPPPPPConclusion: Modified Erchentang can alleviate the process of pulmonary inflammation and pulmonary vascular remodeling in COPD rats, and slow down the progress of COPD and its complications by increasing the content of IL-4, inhibiting the expression of VEGF, VEGFR2, ET-1.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA